Bioventus Inc. · NASDAQ:BVS
Bioventus — J.P. Morgan Healthcare Conference 2023
13 slides from Bioventus's conference presentation, January 2023
Slide 1: Innovations for Active Healing
INNOVATIONS FOR ACTIVE HEALING J.P. Morgan Healthcare Conference Ken Reali January 2023 Chief Executive Officer
Slide 2: Forward-Looking Statements
Innovations For Active Healing Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentati
Slide 3: Bioventus Today
Innovations For Active Healing BIOVENTUS TODAY MARKET LEADERSHIP INNOVATION & DEVELOPMENT VALUE CREATION $517M1 Global Revenue 40%2 of +11% CAGR Surgical 150 Strong Revenue Solutions 120 Revenue from Pain 90 Products Momentum Treatments 60 Launched 2016-2021 30 - since 2018 Restorative 2018 2019 202
Slide 4: Bioventus: A Compelling Investment Opportunity
Innovations For Active Healing BIOVENTUS: A COMPELLING INVESTMENT OPPORTUNITY Delivering diversified technology- and market-leading therapies across the spectrum of orthopedic specialties to generate enhanced scale and profitability Category leader with Innovative, new Demonstrated M&A differentiate
Slide 5: Strategic Building Blocks for Growth as Category Leader
Innovations For Active Healing STRATEGIC BUILDING BLOCKS FOR GROWTH AS CATEGORY LEADER Positioned to Benefit from Favorable Demographics and Tailwinds Across Call Points 50M Americans living Opioid dependency Osteoarthritis projected 50% Increase in 1 in Chronic Pain can begin within to rise to ~78M
Slide 6: Expanding Addressable Market and Accelerating Growth with Recent M&A
Innovations For Active Healing EXPANDING ADDRESSABLE MARKET AND ACCELERATING GROWTH WITH RECENT M&A Surgical Solutions Pain Treatments Surgical Pain Treatments Solutions ~4x Increase in TAM $4.5B Bioness, Misonix and $16.0B 2016 TAM 2022 TAM CartiHeal Acquisitions Restorative Therapies Restorative T
Slide 7: 2023 Priorities
Innovations For Active Healing 2023 PRIORITIES • Recognize restructuring savings and prioritize spending to boost EBITDA Enhance Liquidity to Meet CartiHeal • Complete non-core asset divestiture(s) Milestones • Amend existing credit agreement Complete • Complete integration of Misonix by year-end wi
Slide 8: Enhancing Liquidity to Fund Upcoming CartiHeal Milestones
ENHANCING LIQUIDITY TO FUND UPCOMING CARTIHEAL MILESTONES Executing multiple levers to improve liquidity 1 Restructure 2 Prioritize 3 Divest • Announced restructuring • Prioritize CartiHeal • Non-core asset(s) in December investments • Active processes began in • Anticipate $9 - $10 • Aggressively m
Slide 9: Accessing Breakthrough Technology with CartiHeal Acquisition
ACCESSING BREAKTHROUGH TECHNOLOGY WITH CARTIHEAL ACQUISTION CartiHeal Overview Breakthrough Technology Demonstrates Superiority • Only “off-the-shelf” implant designed to address osteochondral defects in the knee with and without OA • Unlocks applications for the millions of patients in the global k
Slide 10: Unlocking Significant Growth Potential with CartiHeal
Innovations For Active Healing UNLOCKING SIGNIFICANT GROWTH POTENTIAL WITH CARTIHEAL Measured Market Development to Align Private Payers on Reimbursement $2.6B Addressable Market Pathway for Establishing Reimbursement Initially covered as First 100 cases a Category III Code completed in (effective J
Slide 11: Strengthening Portfolio with Growth-Accretive M&A
Innovations For Active Healing STRENGTHENING PORTFOLIO WITH GROWTH – ACCRETIVE M&A Completing Integrations and Realizing Synergies in 2023 + + Acquired: October 2021 Acquired: March 2021 Acquired: July 2022 Complete integration by end of Integration completed in Q1 Initial launch in Q4 2022 2023 202
Slide 12: Enhancing Growth with Innovation
Innovations For Active Healing ENHANCING GROWTH WITH INNOVATION Increased Sales Mix from R&D and Product Development New Product1 Revenue as % of Sales2 Market Development Capabilities 60.0% Leverage existing sales relationships and 50.0% call point overlap to go deeper with 40.0% customers 30.0% Dr
Slide 13: Bioventus: A Compelling Investment Opportunity
Innovations For Active Healing BIOVENTUS: A COMPELLING INVESTMENT OPPORTUNITY Category Leadership Across Growing Markets Diversified Portfolio of Current and Future Growth Drivers Expanded Addressable Market Opportunity Focused Deleveraging through Multiple Strategic Pathways